Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 41.00
Ask: 42.00
Change: -0.10 (-0.24%)
Spread: 1.00 (2.439%)
Open: 42.50
High: 42.40
Low: 41.25
Prev. Close: 42.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor teach-in

13 Jan 2014 07:00

RNS Number : 4298X
Avacta Group PLC
13 January 2014
 



 

Avacta Group plc

("Avacta" or the "Group")

 

Investor teach-in

 

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces it will be hosting an investor teach-in on 5 February 2014 where Alastair Smith, CEO, will provide an overview of the Avacta business. No new material information will be disclosed.

 

Matt Johnson, who recently joined Avacta from Abcam as the Head of Research & Development of Avacta's Life Sciences division, will discuss the opportunity for Affimers, Avacta's proprietary affinity reagent platform.

 

The event, which will include a demonstration and showcase of some of the Avacta's products, will be held from 16:30 until 19:30 in the Oriental Room at the London Capital Club, 15 Abchurch Lane, London, EC4N 7BW, followed by drinks and canapés.

 

For more information or to register to attend, contact Walbrook PR (contact details are below).

 

Enquiries:

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or avacta@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFLFMSFLSEFF
Date   Source Headline
24th Apr 20202:05 pmRNSSecond Price Monitoring Extn
24th Apr 20202:00 pmRNSPrice Monitoring Extension
23rd Apr 20204:40 pmRNSSecond Price Monitoring Extn
23rd Apr 20204:35 pmRNSPrice Monitoring Extension
23rd Apr 202010:18 amRNSResult of General Meeting
22nd Apr 20202:30 pmRNSHolding(s) in Company
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
22nd Apr 20207:00 amRNSAvacta/Cytiva Partnership Ahead of Schedule
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
17th Apr 20207:00 amRNSNotice of Results - Update
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20209:05 amRNSSecond Price Monitoring Extn
15th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20205:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202011:05 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 202011:05 amRNSSecond Price Monitoring Extn
8th Apr 202011:00 amRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSAvacta & Cytiva Collaborate on COVID-19 Rapid Test
6th Apr 20205:45 pmRNSHolding(s) in Company
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:01 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSProposed Placing to raise £3.75 million
2nd Apr 20207:01 amRNSAppointment of Joint Broker
2nd Apr 20207:00 amRNSSubscription to raise £2 million
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
24th Mar 20202:06 pmRNSSecond Price Monitoring Extn
24th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSShareholder/Investor Meeting and Presentation
13th Feb 20207:00 amRNSNotice of Results
11th Feb 20207:00 amRNSShare Incentive Plan/Issue of Equity
3rd Feb 20207:00 amRNSAvacta and Daewoong Agreement
29th Jan 20202:45 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSSuccessful initial proof-of-concept

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.